Previous 10 | Next 10 |
Don’t Believe? Then don’t bother reading. Readers familiar with our work may want to skip to the Comparing Details heading below. Blueprint Medicines Corporation ( BPMC ), in a temporary 9% price drawdown, provides an opportunity for prompt recovery capital gain. This...
CAMBRIDGE, Mass. , Oct. 29, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a Research and Development (R&a...
Blueprint Medicines ( BPMC -8.5% ) is down in early trade in reaction to the FDA's decision to split its avapritinib marketing application into two separate NDAs, one for adults with PDGFRA Exon 18 mutant gastrointestinal stromal tumor (GIST) regardless of prior treatment and the o...
CAMBRIDGE, Mass. , Oct. 28, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced an update regarding its New Drug Application (NDA) for avapriti...
Eli Lilly ( LLY ) announced that it had achieved positive results from a phase 1/2 study using the drug selpercatinib to treat RET fusion-positive non-small cell lung cancer ((NSCLC)). This is good clinical data because it adds RET to the list of genetically mutated alterations that can be t...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2019. Please visit our Tracking Ole Andreas Halvorsen's Viking Global...
Eli Lilly (NYSE: LLY ) is up 3% premarket on light volume in reaction to positive results from a Phase 1/2 clinical trial, LIBRETTO-001 , evaluating oral selpercatinib (LOXO-292) as monotherapy in heavily pretreated patients with RET fusion-positive non-small cell lung cancer ...
The biopharmaceutical industry has been exploding, with roughly one new initial public offering every week. There are so many drug developers out there, new and old, that it can be tough to spot the ones about to soar or crash. You could try watching the sky for a shooting star, but that really...
Acasti Pharma (NASDAQ: ACST ) initiated with Buy rating at B. Riley FBR. More news on: Acasti Pharma Inc., Blueprint Medicines Corporation, Dova Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
CAMBRIDGE, Mass. , Aug. 28, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation in the following upcoming investor...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
2024-07-29 07:15:06 ET Barclays analyst issues EQUAL-WEIGHT recommendation for BPMC on July 29, 2024 05:43AM ET. The previous analyst recommendation was Equal-Weight. BPMC was trading at $112.19 at issue of the analyst recommendation. The overall analyst consensus : BUY....
2024-07-29 07:00:10 ET Peter Lawson from Barclays issued a price target of $105.00 for BPMC on 2024-07-29 05:43:00. The adjusted price target was set to $105.00. At the time of the announcement, BPMC was trading at $112.19. The overall price target consensus is at $100.7...
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...